News

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Novartis finally reaches agreement with Alcon’s minority shareholders for full control

15-12-2010

Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major…

AlconMergers & AcquisitionsNovartisOpthalmicsPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top